Home › Compare › ALSE vs ORCC

ALSE vs ORCC: Dividend Comparison 2026

ALSE yields 20000.00% · ORCC yields 9.79%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ALSE wins by $52481917574412746752.00M in total portfolio value
10 years
ALSE
ALSE
● Live price
20000.00%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$52481917574412746752.00M
Annual income
$51,970,745,957,167,775,000,000,000.00
Full ALSE calculator →
ORCC
ORCC
● Live price
9.79%
Share price
$13.48
Annual div
$1.32
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.4K
Annual income
$1.04
Full ORCC calculator →

Portfolio growth — ALSE vs ORCC

📍 ALSE pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodALSEORCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ALSE + ORCC cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
ALSE pays
ORCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ALSE
Annual income on $10K today (after 15% tax)
$1,700,000.00/yr
After 10yr DRIP, annual income (after tax)
$44,175,134,063,592,610,000,000,000.00/yr
ORCC
Annual income on $10K today (after 15% tax)
$832.34/yr
After 10yr DRIP, annual income (after tax)
$0.88/yr
At 15% tax rate, ALSE beats the other by $44,175,134,063,592,610,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ALSE + ORCC for your $10,000?

ALSE: 50%ORCC: 50%
100% ORCC50/50100% ALSE
Portfolio after 10yr
$26240958787206373376.00M
Annual income
$25,985,372,978,583,888,000,000,000.00/yr
Blended yield
99.03%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ORCC right now

ALSE
No analyst data
Altman Z
-1019.4
Piotroski
2/9
ORCC
Analyst Ratings
9
Buy
4
Hold
1
Sell
Consensus: Buy
Price Target
$16.00
+18.7% upside vs current
Range: $16.00 — $16.00
Altman Z
0.5
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ALSE buys
0
ORCC buys
0
No recent congressional trades found for ALSE or ORCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricALSEORCC
Forward yield20000.00% ✓9.79%
Annual dividend / share$2.00 ✓$1.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0% ✓-50%
Portfolio after 10y$52481917574412746752.00M ✓$21.4K
Annual income after 10y$51,970,745,957,167,775,000,000,000.00 ✓$1.04
Total dividends collected$52448189483771600896.00M ✓$1.0K
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: ALSE vs ORCC ($10,000, DRIP)

YearALSE PortfolioALSE Income/yrORCC PortfolioORCC Income/yrGap
1← crossover$2,010,700$2,000,000.00$11,190$489.61+$2.00M → ALSE
2$377,983,225$375,831,775.70$12,229$256.01+$377.97M → ALSE
3$66,433,479,469$66,029,037,418.28$13,216$130.74+$66433.47M → ALSE
4$10,916,985,471,987$10,845,901,648,955.73$14,207$66.02+$10916985.46M → ALSE
5$1,677,384,363,769,318$1,665,703,189,314,291.80$15,234$33.17+$1677384363.75M → ALSE
6$240,985,175,079,139,100$239,190,373,809,905,920.00$16,317$16.62+$240985175079.12M → ALSE
7$32,373,573,631,143,694,000$32,115,719,493,809,017,000.00$17,468$8.32+$32373573631143.68M → ALSE
8$4,066,766,648,320,630,000,000$4,032,126,924,535,306,000,000.00$18,695$4.16+$4066766648320630.00M → ALSE
9$477,730,483,406,513,300,000,000$473,379,043,092,810,300,000,000.00$20,006$2.08+$477730483406513344.00M → ALSE
10$52,481,917,574,412,750,000,000,000$51,970,745,957,167,775,000,000,000.00$21,407$1.04+$52481917574412746752.00M → ALSE

ALSE vs ORCC: Complete Analysis 2026

ALSE — Stock

Alseres Pharmaceuticals, Inc. focuses on developing diagnostic and therapeutic products primarily for disorders in the central nervous system. Its lead product candidate is Altropane, a molecular imaging agent for the diagnosis of Parkinson's disease and dementia. The company was formerly known as Boston Life Sciences, Inc. and changed its name to Alseres Pharmaceuticals, Inc. in June 2007. Alseres Pharmaceuticals, Inc. was founded in 1972 and is based in Auburndale, Massachusetts.

Full ALSE Calculator →

ORCC — BDC

Owl Rock Capital Corporation is a business development company. The fund makes investments in senior secured or unsecured loans, subordinated loans or mezzanine loans and also considers equity-related securities including warrants and preferred stocks also pursues preferred equity investments and common equity investments. Within private equity, it seeks to invest in growth, acquisitions, market or product expansion, refinancings and recapitalizations. It seeks to invest in middle market companies based in the United States, with EBITDA between $10 million and $250 million annually and/or annual revenue of $50 million and $2.5 billion at the time of investment.

Full ORCC Calculator →
📬

Get this ALSE vs ORCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ALSE vs SCHDALSE vs JEPIALSE vs OALSE vs KOALSE vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.